SONO TEK CORP
For the period ended Feb 29, 2024. Filed May 23, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 23, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
| ITEM 11 | EXECUTIVE COMPENSATION |
|---|
The following table sets forth the aggregate remuneration paid or accrued by the Company for fiscal 2024 and fiscal 2023 for each named officer of the Company.
Summary Compensation Table
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards | Option Awards ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|---|---|---|---|
| CEO, Executive Chairman | 2024 | 193,800 | 48,000 | 0 | 15,000 | 7,300 | 264,100 |
| and Director | 2023 | 192,200 | 20,200 | 0 | 15,000 | 6,373 | 233,773 |
| R. Stephen Harshbarger2 | 2024 | 252,300 | 55,000 | 0 | 15,000 | 9,200 | 331,500 |
| CEO, President and Director | 2023 | 249,200 | 23,000 | 0 | 15,000 | 8,167 | 295,367 |
| Stephen J. Bagley | 2024 | 176,500 | 44,000 | 0 | 7,500 | 6,600 | 234,600 |
| Chief Financial Officer | 2023 | 174,800 | 18,500 | 0 | 7,500 | 5,799 | 206,599 |
| Christopher C. Cichetti | 2024 | 179,800 | 37,000 | 0 | 27,500 | 6,500 | 250,800 |
| Vice President – Sales Applications | 2023 | 168,200 | 14,200 | 0 | 7,500 | 5,500 | 195,400 |
All Other Compensation represents Company contributions to the Company’s 401K plan.
Option awards in the above table are calculated using the Black-Scholes options pricing model which is further discussed in Note 4 – Stock Based Compensation, in the Company’s consolidated financial statements.
1 Dr. Coccio stepped down as CEO on January 1, 2024 and became Executive Chairman.
2 Mr. Harshbarger became CEO on January 1, 2024.
Officer Compensation Arrangements
During fiscal 2024, Dr. Coccio was compensated at the rate of $200,000 per annum, until January 2024, at which time his annual base compensation decreased to $160,000.
During fiscal 2024, Mr. Harshbarger was compensated at the rate of $250,000 per annum, until January 2024, at which time his annual base compensation increased to $265,000.
During fiscal 2024, Mr. Bagley was compensated at the rate of $175,000 per annum, until January 2024, at which time his annual base compensation increased to $185,000.
During fiscal 2024, Mr. Cichetti was compensated at the rate of $170,000 per annum, until August 2023, at which time his annual base compensation increased to $185,000 per annum and increased to $200,000 per annum in January 2024.
In addition, each named officer earned bonus compensation based on the achievement of certain operating objectives.
Outstanding Equity Awards at Fiscal Year End
| Name | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date |
|---|---|---|---|---|
| Christopher L. Coccio1 | 4,652 | 1,163 | 6.05 | 11/18/2031 |
| CEO, Executive Chairman and Director | 32,680 | — | 6.26 | 02/17/2032 |
| 2,027 | 2,477 | 5.96 | 11/17/2032 | |
| — | 5,282 | 5.00 | 11/16/2033 | |
| R. Stephen Harshbarger2 | 4,652 | 1,163 | 6.05 | 11/18/2031 |
| CEO, President and Director | 13,072 | 3,268 | 6.26 | 02/17/2032 |
| 1,772 | 2,165 | 5.96 | 11/17/2032 | |
| — | 4,658 | 5.00 | 11/16/2033 | |
| Stephen J. Bagley | 2,750 | — | 4.45 | 01/15/2031 |
| Chief Financial Officer | 7,843 | 1,961 | 6.26 | 02/17/2032 |
| 886 | 1,082 | 5.96 | 11/17/2032 | |
| — | 2,329 | 5.00 | 11/16/2033 | |
| Christopher C. Cichetti | 2,750 | — | 4.45 | 01/15/2031 |
| Vice President – Sales Applications | 7,843 | 1,961 | 6.26 | 02/17/2032 |
| 886 | 1,082 | 5.96 | 11/17/2032 | |
| — | 8,540 | 5.00 | 11/16/2033 |
1 Dr. Coccio stepped down as CEO on January 1, 2024 and became Executive Chairman.
2 Mr. Harshbarger became CEO on January 1, 2024.
Estimated Payments and Benefits Upon Termination or Change in Control
On September 1, 2007, the Company entered into identical Executive Agreements with Stephen J. Bagley, the Company’s Chief Financial Officer and Christopher L. Coccio, the Company’s Executive Chairman. The Company also entered into an Executive Agreement with R. Stephen Harshbarger, the Company’s Chief Executive Officer and President, on March 5, 2008. The agreements, as subsequently amended, provide that in the event of a change of control of the Company followed by a termination of the executives’ employment under certain circumstances, the officers shall receive severance payments equal to two years of the executive’s annual base, commissions and bonus compensation paid by the Company for the previous calendar year.
Based on last year’s salary arrangements, if the rights of the foregoing officers were to be triggered following a change of control, they would be entitled to the following payments from the Company: Stephen J. Bagley $394,000, Christopher L. Coccio $440,000 and R. Stephen Harshbarger $546,000.
Severance Agreements
On October 20, 2017, the Company entered into identical Executive Agreements with Stephen J. Bagley, Chief Financial Officer, Christopher L. Coccio, Executive Chairman and R. Stephen Harshbarger Chief Executive Officer and President. The agreements provide that in the event of termination of the executive’s employment, other than for the cause, the officers shall receive severance payments equal to two weeks of compensation for each full year employed by the Company.
Clawback Policy
On November 16, 2023, our Board adopted an executive compensation recoupment policy consistent with the requirements of the Exchange Act Rule 10D-1 and the Nasdaq listing standards thereunder, to help ensure that incentive compensation is paid based on accurate financial and operating data, and the correct calculation of performance against incentive targets. Our policy addresses recoupment of amounts from performance-based awards paid to all corporate officers, including awards under our equity incentive plans, in the event of a financial restatement to the extent that the payout for such awards would have been less, or in the event of fraud, or intentional, willful or gross misconduct that contributed to the need for a financial restatement.
Compensation of Directors
Each non-employee director receives $2,500 for each meeting attended. Directors who are employees of the Company receive no additional compensation for serving as directors. For the year ended February 29, 2024, director compensation was as follows:
2024 Director Compensation
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Nonqualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|---|---|---|---|
| Eric Haskell | 10,000 | — | 10,0001 | — | — | — | 20,000 |
| Donald F. Mowbray | 10,000 | — | 10,0002 | — | — | — | 20,000 |
| Carol O’Donnell | 10,000 | — | 10,0003 | — | — | — | 20,000 |
| Philip Strasburg | 10,000 | — | 10,0004 | — | — | — | 20,000 |
| Joseph Riemer | 10,000 | — | 10,0005 | — | — | — | 20,000 |
| 1 | During fiscal 2024, Mr. Haskell received a grant of 3,676 options exercisable at $4.79 per share. At the end of fiscal 2024, Mr. Haskell held an aggregate of 23,026 stock options. |
| 2 | During fiscal 2024, Dr. Mowbray received a grant of 3,676 options exercisable at $4.79 per share. At the end of fiscal 2024, Dr. Mowbray held an aggregate of 6,700 stock options. |
| 3 | During fiscal 2024, Ms. O’Donnell received a grant of 3,676 options exercisable at $4.79 per share. At the end of fiscal 2023, Ms. O’Donnell held an aggregate of 13,026 stock options. |
| 4 | During fiscal 2024, Mr. Strasburg received a grant of 3,676 options exercisable at $4.79 per share. At the end of fiscal 2023, Mr. Strasburg held an aggregate of 10,303 stock options. |
| 5 | During fiscal 2024, Dr. Riemer received a grant of 3,676 options exercisable at $4.79 per share. At the end of fiscal 2023, Dr. Riemer held an aggregate of 15,026 stock options. |
Option awards in the above table are calculated using the Black-Scholes options pricing model which is further discussed in Note 4 – Stock Based Compensation, in the Company’s consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.